Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Abstract

Objective:Functional outcomes were measured over a 12-month period in children and adolescents with attention deficit hyperactivity disorder (ADHD) after they received monotherapy.Design:Prospective, observational, noninterventional study.Setting:Conducted in six non-Western countries.Participants:Outpatients 6 to 17 years of age with a verified diagnosis of ADHD in accordance with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), together with their physicians, decided to initiate or switch treatment for ADHD. Patients were prescribed pharmacological monotherapy: methylphenidate (n=221), nootropic agents (n=91), or atomoxetine (n=234).Measurements:Patients were followed for changes in their functional status and quality of life, which were assessed with the Child Health and Illness Profile–Child Edition (CHIP-CE) Achievement domain.Results:At the end of the study, a mean improvement on the CHIP-CE Achievement domain score was observed for all countries and therapies except in Taiwan, where patients received atomoxetine, and in Lebanon, where patients received methylphenidate. No patient experienced a serious adverse event during the study. Four patients discontinued due to a treatment-emergent adverse event.Conclusion:After 12 months of treatment, clinical and functional outcomes were improved in children and adolescents from non-Western countries who initiated and remained on their prescribed pharmacological monotherapy.

Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention‐deficit/hyperactivity disorder

“…The current study was a post‐hoc analysis of data from a noncomparative, prospective, observational, 12‐month trial in 546 outpatients aged 6–17 years from China ( n = 126), Egypt ( n = 90), Lebanon ( n = 59), the Russian Federation ( n = 142), Taiwan ( n = 79), and the United Arab Emirates ( n = 50) (Altin et al ., ) who were diagnosed with ADHD. Patients' diagnoses of ADHD were verified in clinical psychiatric interviews in accordance with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM‐IV‐TR).…”

“…A recent study demonstrated that clinical and functional outcomes were improved in children and adolescents with ADHD from non‐Western countries who initiated and continued taking their prescribed pharmacological treatment (Altin et al ., ). A variety of predictors of medication adherence and persistence in ADHD have been reported previously.…”

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

“…In our main trial, Altin et al. found that, after 12 months of treatment, clinical and functional outcomes were improved in children and adolescents from non‐Western countries who initiated and remained on their prescribed pharmacological monotherapy . The main objective of this post hoc analysis of the aforementioned study was to examine clinical and demographical predictors of remission of ADHD in a non‐Western cohort of paediatric and adolescent patients with ADHD treated with atomoxetine or methylphenidate over the course of 12 months.…”

Attention Deficit Hyperactivity Disorder: Modern Principles of Diagnostics and Treatment

“…Представляют интерес недавно опубликованные результаты международного исследования «Двенадца-тимесячное проспективное наблюдательное исследова-ние функциональных изменений состояния у детей и под-ростков, которым было назначено медикаментозное лечение по поводу синдрома дефицита внимания с гипер-активностью (СДВГ)» [16]. Его целью было определение функциональных изменений у детей и подростков с СДВГ из разных стран, которым в обычных условиях была назначена монотерапия по поводу СДВГ на протяжении 1 года, с помощью оценки по разделу «Собственные достижения» шкалы CHIP-CE [17].…”

“…Значительный регресс симптомов СДВГ был достигнут к концу исследования во всех трех терапевтических груп-пах. Одновременно во всех группах улучшилась средняя оценка по разделу «Собственные достижения» шкалы CHIP-CE (диапазон изменений в группах 2,0-19,0), что также отражает существенные положительные результа-ты проведенной терапии [16].…”